Véronique Debien, Medical Oncologist at Institute Bergonié, shared a post on LinkedIn:
“Back from AACR26 with a strong sense of momentum.
Great to see several studies involving our team presented, and to engage with pharma and biotech partners on the next wave of early clinical development.
One thing is clear: innovation in oncology is accelerating, citing only KRAS and ADC, but impact will depend on how effectively we translate science into the right trials.
Key challenges remain:
- Identifying the right patients, earlier
- Designing smarter, more adaptive trials
- Integrating robust translational strategies from the start
At Early Phase unite Unité de Phases Précoces – Institut Bergonié CLIP2 at Institut Bergonié, a comprehensive cancer center, our focus is to help bridge discovery and patient benefit by contributing to efficient first-in-human and early development studies.
AACR continues to highlight the importance of strong collaboration, including between industry and academic actors, to advance the most promising therapies.
Expecting ANSM Agence nationale de sécurité du médicament et des produits de santé frameworks, initiatives like FASTTRACK to further facilitate bringing innovation to our patients.”
Other articles featuring Véronique Debien on OncoDaily.